Fifth Third Wealth Advisors LLC Purchases New Position in Hims & Hers Health, Inc. $HIMS

Fifth Third Wealth Advisors LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 4,617 shares of the company’s stock, valued at approximately $230,000.

Several other large investors have also recently added to or reduced their stakes in the stock. SLT Holdings LLC acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $405,000. Blue Trust Inc. increased its holdings in Hims & Hers Health by 95.9% in the 2nd quarter. Blue Trust Inc. now owns 3,767 shares of the company’s stock valued at $188,000 after purchasing an additional 1,844 shares in the last quarter. Total Wealth Planning & Management Inc. acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $593,000. IFP Advisors Inc increased its holdings in Hims & Hers Health by 154.3% in the 2nd quarter. IFP Advisors Inc now owns 2,108 shares of the company’s stock valued at $114,000 after purchasing an additional 1,279 shares in the last quarter. Finally, Baldwin Wealth Partners LLC MA increased its holdings in Hims & Hers Health by 15.5% in the 2nd quarter. Baldwin Wealth Partners LLC MA now owns 25,261 shares of the company’s stock valued at $1,259,000 after purchasing an additional 3,390 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $54.12 on Wednesday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a one year low of $18.33 and a one year high of $72.98. The company’s 50-day simple moving average is $50.66 and its 200-day simple moving average is $48.33. The stock has a market capitalization of $12.23 billion, a price-to-earnings ratio of 67.65, a PEG ratio of 3.74 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period in the previous year, the business posted $0.06 EPS. The business’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer owned 128,984 shares of the company’s stock, valued at $7,139,264.40. This trade represents a 52.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 660,000 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This represents a 22.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,561,799 shares of company stock valued at $80,686,085. Insiders own 17.71% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on HIMS shares. Zacks Research downgraded Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Weiss Ratings restated a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research note on Friday, September 12th. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.